Experience

Y-mAbs Therapeutics Agrees to Acquisition by SERB Pharmaceuticals

August 5, 2025

Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.

Read more

Related contacts

Bill Sorabella
Partner, New York
Bill Roegge
Partner, New York
Div Gupta
Partner, New York
Sarah Sellers
Partner, New York
Christophe Beauduin
Partner, New York
Megan Browdie
Partner, Washington, DC
Brad Goldberg
Partner, New York
Christopher Kimball
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Darah Protas
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Julia Kim
Special Counsel, New York
Justin Kisner
Special Counsel, San Diego
MaryBeth Shreiner
Special Counsel, Reston
Karen Tsai
Special Counsel, Washington, DC
Amanda Weiss
Special Counsel, New York
Rajdeep Roger Bains
Associate, San Diego
Dayne Brown
Associate, New York
Norma Chayo Dichi
Associate, Washington, DC
Sharon Davidov
Associate, New York
Athina Gaki
Associate, Brussels
Kyle Hess
Associate, New York
Katie Kaufman
Associate, Boston
Nicollette R. Kirby
Associate, Washington, DC
Christopher Nickas
Associate, New York
Arda Can Tekin
Associate, New York
Shaun (Tianjie) Wang
Associate, New York

Related Practices & Industries

BioMarin Acquires Inozyme Pharma

May 22, 2025

Cooley advised BioMarin Pharmaceutical (Nasdaq: BMRN), a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient, on its definitive agreement to acquire Inozyme Pharma for $4 per share in an all-cash transaction valued at approximately $270 million.

Read more

Related contacts

Jamie Leigh
Partner, San Francisco
Ben Beerle
Partner, San Francisco
Siana Lowrey
Of Counsel
Chadwick Mills
Partner, San Francisco
Parth Bhatt
Associate, San Francisco
Alex Hammer
Associate, San Francisco
Talya Kornitzer
Associate, New York
Anne Luquette
Associate, San Francisco
Sangitha Palaniappa
Associate, Palo Alto
Tyler Saavedra-Buckley
Associate, San Francisco
Christine Turner
Associate, Colorado
Megan Browdie
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Christophe Beauduin
Partner, New York
Ross Eberly
Partner, Santa Monica
Natasha Leskovsek
Of Counsel, Washington, DC
Barbara Mirza
Partner, Santa Monica

Related Practices & Industries

Chimerix Announces Acquisition by Jazz Pharmaceuticals for $935 Million

March 5, 2025

Cooley advised Chimerix (Nasdaq: CMRX), a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, on its definitive agreement to be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $8.55 per share in cash – totaling approximately $935 million.

Read more

Related contacts

Jason Kent
Partner, New York
Kevin Cooper
Partner, New York
Nathan Baum
Special Counsel, New York
Jamie Leigh
Partner, San Francisco
Izzy Lubarsky
Partner, New York
Susan Choy
Associate, New York
Charlotte Yin
Associate, New York
Angela Kim
Associate, New York
Jane Adams
Partner, San Diego
Christophe Beauduin
Partner, New York
Ross Eberly
Partner, Santa Monica
Stella Sarma
Partner, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Juliana Finley
Associate, Santa Monica
Elizabeth Galvin
Associate, Boston
Carly E. Gibbons
Associate, Chicago
Nathaniel Hearn Jr.
Associate, Chicago
Calvin Lee
Associate, New York
Joseph Perry
Associate, Reston
Greg Reith
Associate, Washington, DC
Freddy Yip
Associate, Hong Kong
Drue Anne Koons
Paralegal Specialist, San Diego

Related Practices & Industries

Nuvation Bio Announces up to $250 Million Nondilutive Financings From Sagard Healthcare Partners

February 18, 2025

Cooley advised Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, on its nondilutive financings of up to $250 million with Sagard Healthcare Partners.

Read more

Related contacts

Mischi a Marca
Partner, San Francisco
Addison Pierce
Partner, Chicago
Shimeng Cheng
Special Counsel, San Francisco
Kenneth Guernsey
Senior Counsel , San Francisco
Rodrigo Huerta
Associate, Chicago
Charles A. Watkins II
Associate, Santa Monica
Dr. Jon Cousin
Partner, Washington, DC
Christophe Beauduin
Partner, New York
Sonia Nath
Partner, Washington, DC
Aaron Pomeroy
Partner, Colorado
Eileen Marshall
Partner, Washington, DC
Michael Neumeister
Partner, Los Angeles
Francis Wheeler
Senior Counsel, Colorado
Stacey A. Bradford
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Melissa H. Boyd
Associate, San Francisco
Cara Buchicchio
Associate, New York
Jameson Davis
Associate, Boston
Auguste Humphries
Associate, Washington, DC
Rick Jantz
Associate, Santa Monica
Allison Kutner
Associate, New York
Shelby Saunders
Associate, New York
Dr. Jason Valentine
Associate, Washington, DC
Jennifer Fitzpatrick
Paralegal Specialist, Washington, DC
Yiming Liu
Partner in Charge – Shanghai, Shanghai

Related Practices & Industries

Flare Therapeutics Announces Strategic Discovery Collaboration With Roche, Potentially Exceeding $1.8 Billion

November 20, 2024

Cooley advised Flare Therapeutics, a clinical-stage biotechnology company, on its strategic discovery collaboration with Roche.

Read more

Related contacts

Christophe Beauduin
Partner, New York
Jiqiang Lin
Associate, New York
Jameson Davis
Associate, Boston
Jonathan Kaufman
Associate, Palo Alto
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Rachel Thorn
Of counsel, New York

Related Practices & Industries

View more

Admissions and credentials

New York

Brussels, Belgium